Peripheral and central biodistribution of 111In-labeled anti-beta-amyloid autoantibodies in a transgenic mouse model of Alzheimer's disease

Michael Bacher, Candan Depboylu, Yansheng Du, Carmen Noelker, Wolfgang H. Oertel, Thomas Behr, Gjermund Henriksen, Martin Behe, Richard Dodel

Research output: Contribution to journalArticle

28 Citations (Scopus)

Abstract

Active as well as passive immunization against beta-amlyoid (Aβ) has been proposed as a treatment to lower cerebral amyloid burden and stabilize cognitive decline in Alzheimer's disease (AD). To clarify the mechanism of action underlying passive immunization, the in vivo distribution (and sites of degradation) of peripherally administered radiolabeled human and mouse anti-Aβ antibodies were analyzed in a transgenic mouse model of AD. In APP23 mice, a model in which mutated human amyloid precursor protein is overexpressed, the biodistribution of intravenously applicated 111indium-conjugated affinity-purified human polyclonal autoantibodies (NAbs-Aβ) was compared to that of monoclonal anti-Aβ1-17 (6E10), anti-Aβ17-24 antibodies (4G8) and anti-CD-20 (Rituximab), a non-Aβ targeting control. Blood clearance half-lives were 50 ± 6 h for Rituximab, 20-30 h for NAbs-Aβ, 29 ± 5 h for 4G8 and 27 ± 3 h for 6E10. Blood activity was higher for 6E10 at 4 h as compared to 4G8, Rituximab and NAbs-Aβ. At the 96 h time point, Rituximab had the highest blood activity among the antibodies tested. As expected, all antibodies displayed hepatobiliary clearance. Additionally, NAbs-Aβ was excreted in the urinary tract. Liver and kidney uptake of NAbs-Aβ increased over time and was higher than in the monoclonal antibodies at 48 h/96 h. The brain-to-blood radioactivity ratio for NAbs-Aβ at later time points (>48 h) was higher than that of 6E10, 4G8 and Rituximab. In addition, the distribution varied, with highest values found in the hippocampus. Our data indicate a cerebral accumulation of human NAbs-Aβ in the APP23 model. Further studies with human immunoglobulins and particularly with those that recognize different Aβ-epitopes are required in order to delineate in more detail the mode of action of NAbs-Aβ.

Original languageEnglish (US)
Pages (from-to)240-245
Number of pages6
JournalNeuroscience Letters
Volume449
Issue number3
DOIs
StatePublished - Jan 16 2009

Fingerprint

Amyloid
Autoantibodies
Transgenic Mice
Alzheimer Disease
Passive Immunization
Anti-Idiotypic Antibodies
A 17
Antibodies
Amyloid beta-Protein Precursor
Urinary Tract
Radioactivity
Immunoglobulins
Epitopes
Hippocampus
Vaccination
Monoclonal Antibodies
Rituximab
Kidney
Liver
Brain

Keywords

  • β-Amyloid
  • Alzheimer's disease
  • Blood-brain barrier
  • Naturally occurring autoantibodies
  • Passive immunization

ASJC Scopus subject areas

  • Neuroscience(all)

Cite this

Peripheral and central biodistribution of 111In-labeled anti-beta-amyloid autoantibodies in a transgenic mouse model of Alzheimer's disease. / Bacher, Michael; Depboylu, Candan; Du, Yansheng; Noelker, Carmen; Oertel, Wolfgang H.; Behr, Thomas; Henriksen, Gjermund; Behe, Martin; Dodel, Richard.

In: Neuroscience Letters, Vol. 449, No. 3, 16.01.2009, p. 240-245.

Research output: Contribution to journalArticle

Bacher, Michael ; Depboylu, Candan ; Du, Yansheng ; Noelker, Carmen ; Oertel, Wolfgang H. ; Behr, Thomas ; Henriksen, Gjermund ; Behe, Martin ; Dodel, Richard. / Peripheral and central biodistribution of 111In-labeled anti-beta-amyloid autoantibodies in a transgenic mouse model of Alzheimer's disease. In: Neuroscience Letters. 2009 ; Vol. 449, No. 3. pp. 240-245.
@article{c52ea980dcd94c8b8ca9cdcc6c6418cc,
title = "Peripheral and central biodistribution of 111In-labeled anti-beta-amyloid autoantibodies in a transgenic mouse model of Alzheimer's disease",
abstract = "Active as well as passive immunization against beta-amlyoid (Aβ) has been proposed as a treatment to lower cerebral amyloid burden and stabilize cognitive decline in Alzheimer's disease (AD). To clarify the mechanism of action underlying passive immunization, the in vivo distribution (and sites of degradation) of peripherally administered radiolabeled human and mouse anti-Aβ antibodies were analyzed in a transgenic mouse model of AD. In APP23 mice, a model in which mutated human amyloid precursor protein is overexpressed, the biodistribution of intravenously applicated 111indium-conjugated affinity-purified human polyclonal autoantibodies (NAbs-Aβ) was compared to that of monoclonal anti-Aβ1-17 (6E10), anti-Aβ17-24 antibodies (4G8) and anti-CD-20 (Rituximab), a non-Aβ targeting control. Blood clearance half-lives were 50 ± 6 h for Rituximab, 20-30 h for NAbs-Aβ, 29 ± 5 h for 4G8 and 27 ± 3 h for 6E10. Blood activity was higher for 6E10 at 4 h as compared to 4G8, Rituximab and NAbs-Aβ. At the 96 h time point, Rituximab had the highest blood activity among the antibodies tested. As expected, all antibodies displayed hepatobiliary clearance. Additionally, NAbs-Aβ was excreted in the urinary tract. Liver and kidney uptake of NAbs-Aβ increased over time and was higher than in the monoclonal antibodies at 48 h/96 h. The brain-to-blood radioactivity ratio for NAbs-Aβ at later time points (>48 h) was higher than that of 6E10, 4G8 and Rituximab. In addition, the distribution varied, with highest values found in the hippocampus. Our data indicate a cerebral accumulation of human NAbs-Aβ in the APP23 model. Further studies with human immunoglobulins and particularly with those that recognize different Aβ-epitopes are required in order to delineate in more detail the mode of action of NAbs-Aβ.",
keywords = "β-Amyloid, Alzheimer's disease, Blood-brain barrier, Naturally occurring autoantibodies, Passive immunization",
author = "Michael Bacher and Candan Depboylu and Yansheng Du and Carmen Noelker and Oertel, {Wolfgang H.} and Thomas Behr and Gjermund Henriksen and Martin Behe and Richard Dodel",
year = "2009",
month = "1",
day = "16",
doi = "10.1016/j.neulet.2008.08.083",
language = "English (US)",
volume = "449",
pages = "240--245",
journal = "Neuroscience Letters",
issn = "0304-3940",
publisher = "Elsevier Ireland Ltd",
number = "3",

}

TY - JOUR

T1 - Peripheral and central biodistribution of 111In-labeled anti-beta-amyloid autoantibodies in a transgenic mouse model of Alzheimer's disease

AU - Bacher, Michael

AU - Depboylu, Candan

AU - Du, Yansheng

AU - Noelker, Carmen

AU - Oertel, Wolfgang H.

AU - Behr, Thomas

AU - Henriksen, Gjermund

AU - Behe, Martin

AU - Dodel, Richard

PY - 2009/1/16

Y1 - 2009/1/16

N2 - Active as well as passive immunization against beta-amlyoid (Aβ) has been proposed as a treatment to lower cerebral amyloid burden and stabilize cognitive decline in Alzheimer's disease (AD). To clarify the mechanism of action underlying passive immunization, the in vivo distribution (and sites of degradation) of peripherally administered radiolabeled human and mouse anti-Aβ antibodies were analyzed in a transgenic mouse model of AD. In APP23 mice, a model in which mutated human amyloid precursor protein is overexpressed, the biodistribution of intravenously applicated 111indium-conjugated affinity-purified human polyclonal autoantibodies (NAbs-Aβ) was compared to that of monoclonal anti-Aβ1-17 (6E10), anti-Aβ17-24 antibodies (4G8) and anti-CD-20 (Rituximab), a non-Aβ targeting control. Blood clearance half-lives were 50 ± 6 h for Rituximab, 20-30 h for NAbs-Aβ, 29 ± 5 h for 4G8 and 27 ± 3 h for 6E10. Blood activity was higher for 6E10 at 4 h as compared to 4G8, Rituximab and NAbs-Aβ. At the 96 h time point, Rituximab had the highest blood activity among the antibodies tested. As expected, all antibodies displayed hepatobiliary clearance. Additionally, NAbs-Aβ was excreted in the urinary tract. Liver and kidney uptake of NAbs-Aβ increased over time and was higher than in the monoclonal antibodies at 48 h/96 h. The brain-to-blood radioactivity ratio for NAbs-Aβ at later time points (>48 h) was higher than that of 6E10, 4G8 and Rituximab. In addition, the distribution varied, with highest values found in the hippocampus. Our data indicate a cerebral accumulation of human NAbs-Aβ in the APP23 model. Further studies with human immunoglobulins and particularly with those that recognize different Aβ-epitopes are required in order to delineate in more detail the mode of action of NAbs-Aβ.

AB - Active as well as passive immunization against beta-amlyoid (Aβ) has been proposed as a treatment to lower cerebral amyloid burden and stabilize cognitive decline in Alzheimer's disease (AD). To clarify the mechanism of action underlying passive immunization, the in vivo distribution (and sites of degradation) of peripherally administered radiolabeled human and mouse anti-Aβ antibodies were analyzed in a transgenic mouse model of AD. In APP23 mice, a model in which mutated human amyloid precursor protein is overexpressed, the biodistribution of intravenously applicated 111indium-conjugated affinity-purified human polyclonal autoantibodies (NAbs-Aβ) was compared to that of monoclonal anti-Aβ1-17 (6E10), anti-Aβ17-24 antibodies (4G8) and anti-CD-20 (Rituximab), a non-Aβ targeting control. Blood clearance half-lives were 50 ± 6 h for Rituximab, 20-30 h for NAbs-Aβ, 29 ± 5 h for 4G8 and 27 ± 3 h for 6E10. Blood activity was higher for 6E10 at 4 h as compared to 4G8, Rituximab and NAbs-Aβ. At the 96 h time point, Rituximab had the highest blood activity among the antibodies tested. As expected, all antibodies displayed hepatobiliary clearance. Additionally, NAbs-Aβ was excreted in the urinary tract. Liver and kidney uptake of NAbs-Aβ increased over time and was higher than in the monoclonal antibodies at 48 h/96 h. The brain-to-blood radioactivity ratio for NAbs-Aβ at later time points (>48 h) was higher than that of 6E10, 4G8 and Rituximab. In addition, the distribution varied, with highest values found in the hippocampus. Our data indicate a cerebral accumulation of human NAbs-Aβ in the APP23 model. Further studies with human immunoglobulins and particularly with those that recognize different Aβ-epitopes are required in order to delineate in more detail the mode of action of NAbs-Aβ.

KW - β-Amyloid

KW - Alzheimer's disease

KW - Blood-brain barrier

KW - Naturally occurring autoantibodies

KW - Passive immunization

UR - http://www.scopus.com/inward/record.url?scp=57149090475&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=57149090475&partnerID=8YFLogxK

U2 - 10.1016/j.neulet.2008.08.083

DO - 10.1016/j.neulet.2008.08.083

M3 - Article

C2 - 18786612

AN - SCOPUS:57149090475

VL - 449

SP - 240

EP - 245

JO - Neuroscience Letters

JF - Neuroscience Letters

SN - 0304-3940

IS - 3

ER -